MetaCap

Gossamer Bio (GOSS) vs MAIA Biotechnology (MAIA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MAIA Biotechnology (MAIA) has outperformed Gossamer Bio (GOSS) over the past year, gaining 21.7% versus a loss of 95.6%. MAIA Biotechnology is the larger company by market cap ($68.5 million vs $65.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GOSS-95.62%MAIA+21.71%
+239%+63%-113%
Nov 21, 20251 yearNov 20, 2026
GOSS-98.81%MAIA-80.86%
+34%-36%-105%
Jul 25, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GOSS versus MAIA key metrics
MetricGOSSMAIA
Share price$10.72$1.11
Market cap$65.57M$68.54M
1-day change-4.54%-2.63%
YTD return-95.68%-27.45%
1-year return-95.62%+21.71%
5-year return-98.74%—
EPS (TTM)$-42.41$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$48.47M—
Revenue growth (YoY)-57.74%—
Net income (latest FY)$-170.37M$-22.40M
Operating margin-352.23%—
Net margin-351.49%—
52-week high$309.60$3.19
52-week low$8.29$0.895
Distance from 52-week high-96.54%-65.20%
Analyst consensusbuynone
Avg. price target upside+669.40%+981.08%
Average volume243.40K524.29K
Shares outstanding6.12M61.75M
Employees16113
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MAIA has outperformed GOSS by 117.3 percentage points over the past year.

About Gossamer Bio

GOSS stock →

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

About MAIA Biotechnology

MAIA stock →

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

GOSS vs MAIA FAQ

Which is bigger, Gossamer Bio or MAIA Biotechnology?

MAIA Biotechnology (MAIA) is larger, with a market capitalization of $68.54M compared with $65.57M for Gossamer Bio (GOSS).

Which stock has performed better over the past year, GOSS or MAIA?

MAIA returned +21.71% over the past 12 months, compared with -95.62% for GOSS (price return, excluding dividends). Past performance does not predict future results.

Are Gossamer Bio and MAIA Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons